Detroit, MI Clinical Trials Report — July 2026

Detroit participants should act now if they match a study nearing its enrollment window: 34 recruiting trials are expected to close within the next 90 days. Four of those closing studies accept healthy volunteers. Detroit currently has 747 recruiting trials across 198 research facilities, so people who do not qualify for one study may still have other local options.

New activity remains steady. Detroit opened 8 trials in July, up from 7 in June and May’s 6. The new studies cover cancer, behavioral health, alcohol use disorder, digital health, and disruptive behaviors, with drug studies making up the largest category.

Closing windows for Detroit participants

Enrollment can end earlier than a projected closing date if a study reaches its participant target. People with the following conditions should review eligibility and contact study teams promptly:

• Pancreatic ductal adenocarcinoma (2 trials)
• Head and neck cancer (2 trials)
• Prostate cancer (2 trials)
• Advanced solid tumors (2 trials)
• Acute myeloid leukemia, including AML with mutated NPM1 (2 trials combined)
• Advanced high-grade epithelial ovarian cancer (1 trial)
• Atrial arrhythmia or atrial tachycardia (2 trials combined)
• Atopic dermatitis (1 trial)

Four of the 34 closing-soon studies accept healthy volunteers. Across Detroit, 42 trials are currently recruiting healthy participants, but none of July’s eight new trials accepts healthy volunteers. Healthy volunteers considering research should therefore search the existing pool rather than waiting for the newest openings. Screening may involve age requirements, medication restrictions, health tests, and scheduled visits.

New Phase 2 and Phase 3 studies at local sites

July’s openings include 5 drug trials, 3 behavioral studies, 1 biological study, 1 diagnostic test, and 1 study classified as other. Several large late-stage studies sponsored by industry or local academic institutions are particularly notable:

• Akeso is sponsoring NCT07700979, a Phase 3 study of cadonilimab combined with chemotherapy for previously untreated, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. The study plans to enroll 900 participants.
• AstraZeneca is sponsoring NCT07735637, a Phase 3 study comparing AZD0120 with autologous stem cell transplant as consolidation treatment for transplant-eligible people with newly diagnosed multiple myeloma. Planned enrollment is 750 participants.
• TScan Therapeutics, Inc. is conducting NCT07702578, a Phase 3 study of T-cell receptor-engineered donor T cells following allogeneic peripheral blood stem cell transplantation. The study expects 310 participants.
• Barbara Ann Karmanos Cancer Institute is sponsoring NCT07735819, a Phase 2 study evaluating PET/CT imaging with an investigational radiotracer in people diagnosed with a glioma. Planned enrollment is 61 participants.

The new-condition list also includes AML, malignant lung neoplasm, malignant head and neck neoplasm, low-grade glioma, and behavioral health. The eight new trials include 4 industry-sponsored studies and 4 sponsored by other organizations, including Henry Ford Health System, Wayne State University, Brandeis University, and local cancer research institutions.

Detroit’s largest research facilities

Henry Ford and Karmanos-affiliated sites account for much of Detroit’s research access. Henry Ford Hospital leads the city with 139 recruiting trials. Karmanos Cancer Institute has 92, while Henry Ford Health System has 71. These sites provide particularly strong options for oncology and hospital-based research, while Wayne State University and the Detroit VA add academic and veterans-focused opportunities.

• Henry Ford Hospital (139 trials)
• Karmanos Cancer Institute (92 trials)
• Henry Ford Health System (71 trials)
• Henry Ford Health (47 trials)
• Wayne State University/Karmanos Cancer Institute (46 trials)
• Henry Ford Health Saint John Hospital (43 trials)
• Research Site (40 trials)
• Children’s Hospital of Michigan (38 trials)
• Wayne State University (22 trials)
• Barbara Ann Karmanos Cancer Institute (19 trials)
• Henry Ford Cancer Institute (12 trials)
• John D. Dingell VA Medical Center (9 trials)

People seeking cancer studies should start with Karmanos, Barbara Ann Karmanos Cancer Institute, Henry Ford Cancer Institute, and Henry Ford-affiliated hospitals. Children’s Hospital of Michigan is the leading listed option for pediatric research, although none of July’s new trials includes children. None of the new openings is female-only or male-only, and all 8 include older adults.

Other Michigan cities to consider

Detroit has the state’s strongest local concentration in this dataset, but participants willing to travel can also check nearby Michigan markets. Ann Arbor has 9 recruiting trials, followed by Grand Rapids with 5. Southfield and Flint each have 2, while Dearborn, Berkeley, Berkley, and Livonia each have 1.

With new openings holding near recent monthly levels and dozens of studies approaching their projected closing dates, July is a practical time to compare eligibility across Detroit’s major hospital and university sites. Patients with the listed cancer, cardiac, skin, or blood conditions—and healthy volunteers seeking one of the remaining openings—should contact research teams early as enrollment activity continues into late summer.